A Case Report: the Role of Prostate-Specific Membrane Antigen Labeled Theranostic Agents in the Diagnosis and Treatment of Prostate Cancer

Basit Öğe Kaydı
dc.contributor.authorAvul, Ali Rıza
dc.contributor.authorÖzdemir, Büşra
dc.contributor.authorAltun, Gülay Durmuş
dc.date.accessioned2021-11-20T10:26:55Z
dc.date.available2021-11-20T10:26:55Z
dc.date.issued2019
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Anabilim Dalıen_US
dc.description.abstractAims: Prostate cancer is one of the most prevalent cancers worldwide and sometimes it can be deadly which brings out a high quantity of the prostate specific membrane antigen. Gallium-68 prostate specific membrane antigen PET scan is used to detect primary tumors and metastases of prostate cancer. In addition, Lutetium-177 prostate-specific membrane antigen is used for treatment in some special cases. Our case report aims to show the roles of prostate specific membrane antigen labeled theranostic agents in the diagnosis, staging, and treatment of prostate cancer and evaluate the response to the treatment of metastatic castration-resistant prostate cancer. Case Report: A 78-year-old male patient was admitted to Trakya University Hospital Nuclear Medicine Department with the diagnosis of prostate cancer for cancer staging and treatment. Gallium-68 prostate specific membrane antigen was firstly used to detect any metastases and then to evaluate response to the treatment. Lutetium-177 prostate specific membrane antigen was used for treatment. Conclusion: After 3 cures of Lutetium-177 therapy, the patient underwent Gallium - 68 prostate specific membrane antigen PET which demonstrated regression of the metastatic tumor. There was a decrease in the uptake of Gallium-68 prostate specific membrane antigen in the primary tumor and lymph nodes metastases. Also, bone metastases have been cleared. Hence, Lutetium-177 seems to be a promising treatment modality to treat metastatic prostate canceren_US
dc.identifier.dergipark541685en_US
dc.identifier.issn2148-4724
dc.identifier.issn2548-0030
dc.identifier.issue1en_US
dc.identifier.urihttps://dergipark.org.tr/tr/pub/tmsj/issue/43969/541685
dc.identifier.urihttps://dergipark.org.tr/tr/download/article-file/674002
dc.identifier.urihttps://hdl.handle.net/20.500.14551/6225
dc.identifier.volume6en_US
dc.language.isoenen_US
dc.publisherTrakya Üniversitesien_US
dc.relation.ispartofTurkish Medical Student Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProstate canceren_US
dc.subjecttheranosticen_US
dc.subjectlutetiumen_US
dc.titleA Case Report: the Role of Prostate-Specific Membrane Antigen Labeled Theranostic Agents in the Diagnosis and Treatment of Prostate Canceren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
6225.pdf
Boyut:
320.41 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Turkish Medical Student Journal
Makale Koleksiyonu